Pharmaceutical formulation comprising a pyrimidine-a-one derivative coated with an enteric polymer
CA 2537178 C · Owner: Glaxosmithkline Research And Development Limited · Inventors: Van Schie, Dirk Marinus Johannes
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides enteric polymer coated tablet formulations for oral administration which comprise a phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2 (Lp-PLA2) inhibitor processes for preparing such , formulations and their use in therapy in particular the treatment of , atherosclerosis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 31, 2004 and granted March 19, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 31, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 31, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.